本文までスキップする

Emerging Medicine
for Integrated Therapeutics

CONTACT
JP

2025年

  1. Tanaka N, Shinohara A, Kimura SI, Kobayashi S, Uchida N, Asada N, Ota S, Tanaka M, Arai Y, Kataoka K, Hagihara M, Onizuka M, Nakamura Y, Matsuoka KI, Kawamura K, Kanda J, Fukuda T, Atsuta Y, Nakasone H. The Limited Impact of Pre-existing Rheumatologic Diseases on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Propensity-Score Matched Analysis. Transplant Cell Ther. 2025 Nov 5:S2666-6367(25)01550-7. doi: 10.1016/j.jtct.2025.11.002. Epub ahead of print. PMID: 41203077.
  2. Kurita N, Maruo K, Kimura F, Kuwatsuka Y, Matsukawa T, Konuma T, Kobayashi S, Sakata-Yanagimoto M, Doki N, Tanaka M, Uchida N, Nishida T, Sawa M, Hasegawa Y, Nakamae H, Ota S, Onizuka M, Fukuda T, Hiramoto N, Kawakita T, Asada N, Ishimaru F, Kanda J, Tabuchi K, Atsuta Y, Nakasone H; Donor/Source and Transplant Complications Working Groups of the Japanese Society for Transplantation and Cellular Therapy. Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective Study. Am J Hematol. 2026 Jan;101(1):193-197. doi:10.1002/ajh.70124. Epub 2025 Oct 29. PMID: 41159671.
  3. Kikuchi J, Osada N, Matsuoka S, Yasui H, Furukawa Y, Nakasone H. Structure-based prediction reveals a difference in the binding mode of anti-BCMA antibodies to BCMA and soluble BCMA. Leukemia. 2025 Oct 24. doi:10.1038/s41375-025-02792-3. Epub ahead of print. PMID: 41136753.
  4. Akahoshi Y, Bejanyan N, Nakasone H, Kusuda M, Tada Y, Sakaida E, Atsuta Y, Kanda Y, Fukuda T. Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec 4:S2666-6367(25)01612-4. doi: 10.1016/j.jtct.2025.11.036. Epub ahead of print. PMID: 41352454; PMCID: PMC12698115.
  5. Yanada M, Yamasaki S, Mizuno S, Sugita J, Fujino T, Misaki Y, Tanaka M, Uchida N, Onizuka M, Doki N, Ota S, Sawa M, Kawakita T, Hasegawa Y, Nakamae H, Ishiwata K, Hiramoto N, Ishimaru F, Kanda J, Ohbiki M, Atsuta Y, Nakasone H, Konuma T. Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia. Bone Marrow Transplant. 2025 Oct 5. doi: 10.1038/s41409-025-02729-5. Epub ahead of print. PMID: 41046309.
  6. Sakurai M, Kataoka K, Mizuno K, Mori T, Shirane S, Sakaguchi H, Mori T, Tanaka M, Tokunaga M, Onizuka M, Sakata-Yanagimoto M, Ishikawa J, Katayama Y, Ota S, Sawa M, Kato J, Hasegawa Y, Onodera K, Hattori N, Miyakoshi S, Takayama N, Nishida T, Kato K, Ishimaru F, Atsuta Y, Kanda J, Nakasone H, Terakura S. Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults. Am J Hematol. 2025 Dec;100(12):2248-2260. doi: 10.1002/ajh.70094. Epub 2025 Sep 26. PMID: 41002003; PMCID: PMC12603891.
  7. Matsuoka S, Osada N, Kubota H, Kikuzato K, Koyama H, Sonoda T, Idei A, Yoshida M, Kikuchi M, Umehara T, Watanabe C, Honma T, Yasui H, Ikeda S, Takahashi N, Nakasone H, Kikuchi J, Furukawa Y. Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14). Blood Neoplasia. 2025 Mar 11;2(2):100091. doi: 10.1016/j.bneo.2025.100091. PMID: 40949769; PMCID: PMC12423681.
  8. Fuse Y, Sasaki E, Tamaki M, Kawamura S, Ohno H, Yamada S, Yasunaga M, Takakura H, Hanaoka H, Kobayashi H, Nakasone H, Hanaoka K. Development of a silicon phthalocyanine analogue for near-infrared photoimmunotherapy and its application to HTLV-1-infected leukemic cells. RSC Chem Biol. 2025 Aug 5;6(10):1576-1584. doi: 10.1039/d5cb00150a. PMID: 40837968; PMCID: PMC12360215.
  9. Kikuchi J, Osada N, Matsuoka S, Ohta T, Kazama H, Shirai H, Meloni M, Chiron M, Yasui H, Nakasone H, Furukawa Y. FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q. Haematologica. 2025 Jul 31. doi: 10.3324/haematol.2025.287904. Epub ahead of print. PMID: 40820736.
  10. Konuma T, Kanda J, Uchida N, Tanaka M, Kimura F, Nakasone H, Uehara Y, Tokunaga M, Toyosaki M, Miyakoshi S, Doki N, Ishiwata K, Kobayashi H, Onishi Y, Kozai Y, Kato K, Ishimaru F, Fukuda T, Atsuta Y, Takahashi S. Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan. Br J Haematol. 2025 Nov;207(5):2026-2040. doi: 10.1111/bjh.70099. Epub 2025 Aug 16. PMID: 40817823; PMCID: PMC12624182.
  11. Shimomura Y, Komukai S, Kitamura T, Yoshimura K, Inamoto Y, Akahoshi Y, Kuwatsuka Y, Usui Y, Uchida N, Tanaka M, Onizuka M, Sakata-Yanagimoto M, Doki N, Hasegawa Y, Ishiwata K, Nakamae H, Sawa M, Katayama Y, Kawakita T, Yoshimitsu M, Fukuda T, Kanda Y, Ohbiki M, Nakasone H, Kanda J. A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors. Br J Haematol. 2025 Sep;207(3):946-955. doi: 10.1111/bjh.70008. Epub 2025 Jul 16. PMID: 40671206.
  12. Akahoshi Y, Inamoto Y, Spyrou N, Nakasone H, Diniz MA, Asada N, Ayuk F, Choe HK, Doki N, Eto T, Etra AM, Hexner EO, Hiramoto N, Hogan WJ, Holler E, Kataoka K, Kawakita T, Tanaka M, Tanaka T, Uchida N, Vasova I, Yoshihara S, Ishimaru F, Fukuda T, Chen YB, Kanda J, Nakamura R, Atsuta Y, Ferrara JLM, Kanda Y, Levine JE, Teshima T. Refinement of day 28 treatment response criteria for acute GVHD:a collaboration study of the JSTCT and MAGIC. Blood Adv. 2025 Sep 23;9(18):4640-4653. doi: 10.1182/bloodadvances.2025016233. PMID: 40590886; PMCID: PMC12496244.
  13. Yoshimura K, Nakasone H, Tamaki M, Hosoi H, Kameda K, Uchida N, Doki N, Fukuda T, Yoshihara S, Mori Y, Nakamae H, Tanaka M, Katayama Y, Eto T, Hasegawa Y, Ota S, Takahashi S, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Yakushijin K. Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation. Am J Hematol. 2025 Jul;100(7):1185-1195. doi: 10.1002/ajh.27709. Epub 2025 May 23. PMID: 40407015.
  14. Masuda K, Kataoka K, Sakurai M, Najima Y, Harada N, Ukita S, Uchida N, Doki N, Fukuda T, Tanaka M, Ohigashi H, Ishikawa J, Yoshihara S, Sawa M, Ota S, Kanda Y, Nishida T, Onizuka M, Atsuta Y, Nakasone H, Yakushijin K. Classical and Late-Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis. Am J Hematol. 2025 Aug;100(8):1283-1294. doi: 10.1002/ajh.27715. Epub 2025 May 19. PMID: 40387331; PMCID: PMC12232550.
  15. Akahoshi Y, Nakasone H, Takenaka K, Ara T, Tada Y, Doki N, Uchida N, TanakaM, Hasegawa Y, Takeda W, Nishida T, Ishikawa J, Kurita N, Sawa M, Onizuka M,Kako S, Fujiwara SI, Kataoka K, Kawamura K, Fukuda T, Atsuta Y, Yakushijin K,Kanda Y. Heterogeneity of Survival Benefit Conferred By Letermovir. Transplant　Cell Ther. 2025 Jul;31(7):461.e1-461.e12. doi: 10.1016/j.jtct.2025.04.010. Epub　2025 Apr 28. PMID: 40306552.
  16. Nakaya Y, Nakamae H, Nakasone H, Okamura H, Harada N, Kawamura K, Terakura S, Hasegawa Y, Eto T, Fukuda T, Hiramoto N, Nagafuji K, Ota S, Maruyama Y, Kawakita T, Matsuoka KI, Doki N, Kamimura T, Ando T, Akasaka T, Atsuta Y, Kanda J. Dose Effect of Antithymocyte Globulin or Post-transplant Cyclophosphamide in Haploidentical Peripheral Blood Stem Cell Transplantation: A Comparative Study. Transplant Cell Ther. 2025 Aug;31(8):544.e1-544.e5. doi:10.1016/j.jtct.2025.04.007. Epub 2025 Apr 26. PMID: 40294821.
  17. Nakamura N, Morishita T, Hayashi H, Okabe M, Nakasone H, Uchida N, Doki N, Fukuda T, Yoshihara S, Tanaka M, Nishida T, Hasegawa Y, Matsuoka KI, Sawa M, Eto T, Onizuka M, Katayama Y, Kato K, Ishimaru F, Tabuchi K, Atsuta Y, Kanemura N, Teshima T. The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis. Bone Marrow Transplant. 2025 Jul;60(7):964-970. doi: 10.1038/s41409-025-02588-0.Epub 2025 Apr 17. PMID: 40240501; PMCID: PMC12234360.
  18. Osada N, Kikuchi J, Matsuoka S, Yasui H, Ikeda S, Takahashi N, Furukawa Y, Nakasone H. c-FOS Confers Stem Cell-like Features to Multiple Myeloma Cells in a Bone Marrow Microenvironment. Cells. 2025 Mar 21;14(7):474. doi: 10.3390/cells14070474. PMID: 40214428
  19. Nagayama T, Fujiwara SI, Nishiwaki S, Wada F, Uchida N, Tanaka M, Sakata-Yanagimoto M, Onizuka M, Ishiwata K, Hasegawa Y, Ota S, Doki N, Nakamae H, Nishida T, Kawakita T, Sawa M, Tokunaga M, Ishimaru F, Fukuda T, Kanda Y, Atsuta Y, Nakasone H. Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation. Blood Adv. 2025 Jul 8;9(13):3226-3237. doi: 10.1182/bloodadvances.2024014938. PMID: 40085961; PMCID: PMC12246605.
  20. Misaki Y, Tamaki M, Yanagisawa R, Doki N, Uchida N, Tanaka M, Nishida T, Sawa M, Hasegawa Y, Ota S, Onizuka M, Mamiko SY, Katayama Y, Asada N, Kanda J, Fukuda T, Atsuta Y, Kanda Y, Yakushijin K, Nakasone H. Adverse Impact of Pre-Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation. Am J Hematol. 2025 May;100(5):821-829. doi: 10.1002/ajh.27652. Epub 2025 Mar 8. PMID: 40056058
  21. Wada F, Iwasaki M, Hirayama M, Kawamura K, Kaida K, Doki N, Nakamae H, Hasegawa Y, Fukuda T, Eto T, Hiramoto N, Maruyama Y, Nagafuji K, Ota S, Ishikawa J, Ando T, Ichinohe T, Atsuta Y, Nakasone H, Kanda J. Donor selection in T-cell-replete haploidentical donor peripheral blood stem cell transplantation. Leukemia. 2025 Apr;39(4):951-961. doi: 10.1038/s41375-025-02538-1. Epub 2025 Feb 19. PMID: 39972117
  22. Ishikawa T, Kawamura M, Takeshita J, Ito S, Wada H, Matsuda Y, Sanayama H, Ominami S, Nakata Y, Meno T, Matsuoka A, Nakamura Y, Kawamura S, Yoshino N, Misaki Y, Gomyo A, Kusuda M, Kimura SI, Nakasone H, Kako S, Kanda Y. [Bickerstaff brainstem encephalitis preceding central nervous system relapse of diffuse large B-cell lymphoma]. Rinsho Ketsueki. 2024;65(11):1388-1392. Japanese. doi: 10.11406/rinketsu.65.1388. PMID: 39935226.
  23. Nakata Y, Yoshino N, Kusuda M, Kimura SI, Matsuoka A, Meno T, Ishikawa T, Nakamura Y, Kawamura M, Takeshita J, Kawamura S, Misaki Y, Yoshimura K, Gomyo A, Tamaki M, Hoshino Y, Shinohara T, Miyazaki Y, Nakasone H, Kako S, Kanda Y. Fatal pneumonia with repeated detection of Talaromyces columbinus two years after haploidentical transplantation. J Infect Chemother. 2025 Apr;31(4):102649. doi:10.1016/j.jiac.2025.102649. Epub 2025 Feb 6. PMID: 39922460.
  24. Gomyo A, Kako S, Kawamura M, Kawamura S, Takeshita J, Yoshino N, Misaki Y, Yoshimura K, Matsumi S, Akahoshi Y, Tamaki M, Kusuda M, Kameda K, Wada H, Kawamura K, Sato M, Terasako-Saito K, Kimura SI, Nakasone H, Kanda Y. Rapid tapering of cyclosporine after allogeneic transplantation for high-risk hematological malignancies. Int J Hematol. 2025 Apr;121(4):504-510. doi:10.1007/s12185-024-03913-x. Epub 2025 Feb 6. PMID: 39912986.
  25. Shinohara A, Shindo M, Nakano N, Sakaida E, Uchida N, Fukushima K, NakazawaH, Serizawa K, Kanda Y, Kawakita T, Ikeda T, Ohigashi H, Ito A, Wakayama T, Matsuoka KI, Fukuda T, Tanaka J, Atsuta Y, Nakasone H. Increased Non-Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan-Based Regimen. Eur J Haematol. 2025 May;114(5):852-863. doi: 10.1111/ejh.14374. Epub 2025 Jan 20. PMID: 39834012.
  26. Tomori S, Morishima S, Kato K, Nakasone H, Nakano N, Eto T, Kawakita T, Suehiro Y, Miyazaki Y, Uchida N, Sawayama Y, Mori Y, Nakamae H, Nagafuji K, Uehara Y, Doki N, Kanda J, Fukuda T, Atsuta Y, Yoshimitsu M; JSTCT ATL Working Group and JSTCT Transplant Complications Working Group. Low Survival Due to Higher Risk of Relapse and Nonrelapse Mortality After Allogeneic HSCT in ATL Compared with AML and ALL. TransplantCell Ther. 2025 Apr;31(4):253.e1-253.e14. doi: 10.1016/j.jtct.2025.01.882. Epub 2025 Jan 17. PMID: 39828057.
  27. Kawamura S, Fujiwara SI, Kimura SI, Takeshita J, Nakasone H, Yoshimura K,Nakata Y, Ishikawa T, Matsuoka A, Meno T, Nakamura Y, Kawamura M, Yoshino N, Misaki Y, Gomyo A, Kusuda M, Murahashi R, Umino K, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kako S, Kanda Y. Risk-Adapted Letermovir Prophylaxis Based on a Scoring System Predicting a Higher Burden of Cytomegalovirus Exposure After Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2025 Mar;31(3):184.e1-184.e11. doi:10.1016/j.jtct.2025.01.883. Epub 2025 Jan 17. PMID: 39828058.
  28. Kawamura S, Nakagawa D, Nagayama T, Katayama Y, Doki N, Takeda W, Nishida T, Matsuoka KI, Ikeda T, Ohigashi H, Sawa M, Fukushima K, Kanda J, Serizawa K, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H. Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT. Blood Adv. 2025 May 13;9(9):2356-2365. doi:10.1182/bloodadvances.2024014408. PMID: 39808797; PMCID: PMC12142802.
  29. Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, Nakamae H, Tokunaga M, Ishiwata K, Onizuka M, Hasegawa Y, Fukuda T, Eto T, Kurita N, Kawakita T, Jinguji A, Ishimaru F, Atsuta Y, Nakasone H. Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease. Transplant Cell Ther. 2025 Feb;31(2):103.e1-103.e13. doi: 10.1016/j.jtct.2024.11.011. Epub 2024 Nov 26. PMID: 39603416.
  30. Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, Ouchi F, Uchida N, Tanaka M, Nishida T, Fukuda T, Hasegawa Y, Sakata-Yanagimoto M, Onizuka M, Sawa M, Ota S, Asada N, Fujiwara SI, Yoshihara S, Ishimaru F, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Yanada M. Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type. Am J Hematol. 2025 Jan;100(1):66-77. doi: 10.1002/ajh.27521. Epub 2024 Nov 20.PMID: 39564683Free PMC article.
  31. Tamaki M, Kawamura S, Takano K, Nakamae H, Doki N, Ohigashi H, Maruyama Y, Ota S, Hiramoto N, Eto T, Yoshihara S, Matsuoka KI, Masuko M, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Nakasone H. Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation. 2025 Feb;27(2):213-221. doi: 10.1016/j.jcyt.2024.09.007. Epub 2024 Oct 5.PMID: 39453336
一覧へ戻る